Advances in the Diagnosis, Treatment and Molecular Genetics of Pituitary Adenomas in Childhood

Keil, Margaret F.; Stratakis, Constantine A.

doi:10.17925/ee.2008.04.02.81

Cited by 3 publications

(5 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common childhood/adolescence PA is prolactinomas [ 3 , 8 , 13 , 15 ] and also in the present study. Sixty three percent were prolactinomas and with female predominance which is also similar in the adult population [ 3 , 4 , 18 – 20 , 22 , 24 ].…”

Section: Discussionmentioning

confidence: 82%

“…Medical management of prolactinomas with BRC and CBG are typically first line treatment for the normalization of prolactin levels and restoring pituitary function and reducing tumor size [ 3 , 31 ]. Some authors claim that CBG is more effective and often better tolerated than BRC [ 4 , 22 , 25 , 32 ]. Dopamine agonists are effective in reducing tumor size and controlling prolactin levels in 80–90% of microadenomas and about 70% of macroadenomas [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

“…Pituitary adenoma (PA), although rare and often benign, is a challenging disorder for diagnosis and subsequent management [ 1 ]. The incidence is 0.1 per million children and the prevalence is up to 1 per 1 million children [ 2 – 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pediatric pituitary adenomas in Northeast Mexico. A follow-up study

2018

View full text Add to dashboard Cite

PurposeTo review incidence, treatment and outcome of pediatric pituitary adenomas (PAs).MethodsA follow-up study patients with the age of ≤19 years old who were treated from 1995 to 2015 in Mexico.ResultsOut of 1244 diagnosed PA, 43 patients were children (35 females, 8 males) with a mean age of 17.2 years. The majority were macroadenomas (70%) with prolactinomas (PRL) dominating (63%) followed by non-functioning adenomas (21%). In total, 40% were diagnosed as invasive. Growth hormone (GH) secreting adenomas, adrenocorticotropic hormone secreting and mixed GH-PRL secreting were rare. The treatment modalities were dopamine agonists and surgery. The average treatment time was 44 months with an average follow-up period of 104 months. Sixty-eight percent (27/40) of the patients had complete response after long time follow-up. Thirty-one percent did not respond to treatment whereof three patients died due to advanced disease and late intervention. The principal causes for treatment failure were treatment resistance, late intervention and poor patient compliance.ConclusionsSixty eight percent had complete treatment response without any sign of disease, while ~31% did not respond to treatment or did not comply to follow up/treatment. Optimized early diagnose, treatment methods with early intervention, long time follow-up and with better measures for patient compliance should improve outcomes.

show abstract

Section: Discussionmentioning

confidence: 82%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pediatric pituitary adenomas in Northeast Mexico. A follow-up study

2018

View full text Add to dashboard Cite

show abstract

“…Table 1 lists the studies (n = 19) that were excluded along with the reason for exclusion [ Table 1 ]. [ 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 ] Finally, eight (n = 8) studies were included in this scoping review. [ 34 35 36 37 38 39 40 41 ] Characteristics of all the studies[ 34 35 36 37 38 39 40 41 ] are shown in Table 2 .…”

Section: R Esultsmentioning

confidence: 99%

A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas

Mishra¹,

Konar²,

Shrivastava³

et al. 2021

Indian Journal of Endocrinology and Metabolism

View full text Add to dashboard Cite

Cabergoline has long been used in the medical management of prolactin-secreting pituitary adenomas. However, there is contradicting and inadequate evidence on the efficacy of cabergoline in achieving radiological and biochemical remission in prolactinoma. This article presents scoping review of evidence in cabergoline achieving radiological and biochemical remission in cases of prolactinoma. We have used a recommended scoping review methodology to map and summarize existing research evidence and identify knowledge gaps. The review process was conducted according to the PRISMA-ScR guidelines (Preferred Reporting Items for Systematic reviews and Meta-Analyses Extension for Scoping Reviews). The selection of studies was based on the criteria defined. Essential information such as reference details, study characteristics, topics of interest, main findings, and the study author's conclusion are presented in text and tables. With the study selection process, eight publications were finally included—one systematic review and meta-analysis, one RCT, and six primary studies. Cabergoline is effective in achieving biochemical and radiological remission in cases of prolactinoma. We identified several knowledge gaps with the scoping review and directions for future studies. Future studies, including randomized studies, will help address challenging questions associated with the management of prolactinoma.

show abstract

“…In these cases, somatostatin analogs are recommended for normalization of IGF-1 levels [54]. For the subgroup of patients with normal IGF-1 levels but abnormal responses to the oral glucose-tolerance test and normal pituitary imaging, annual evaluation should be performed for the detection of any changes that might require treatment [54]. …”

Section: Cell Signaling Pathways In Pituitary Tumorigenesismentioning

confidence: 99%

Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways

Xekouki

Azevedo

Stratakis

2010

Expert Review of Endocrinology & Metabolism

Self Cite

View full text Add to dashboard Cite

Pituitary adenomas are common tumors. Although rarely malignant, pituitary adenomas cause significant morbidity due to mass effects and/or hormonal hypo-and/or hyper-secretion. Molecular understanding of pituitary adenoma formation is essential for the development of medical therapies and the treatment of post-operative recurrences. In general, mutations in genes involved in genetic syndromes associated with pituitary tumors are not a common finding in sporadic lesions. By contrast, multiple endocrine neoplasia type 1 (MEN-1) and aryl hydrocarbon receptor-interacting protein (AIP) mutations may be more frequent among specific subgroups of patients, such as children and young adults, with growth hormone-producing adenomas. In this article, we present the most recent data on the molecular pathogenesis of pituitary adenomas and discuss some of the most recent findings from our laboratory. Guidelines for genetic screening and clinical counseling of patients with pituitary tumors are provided.

show abstract

Advances in the Diagnosis, Treatment and Molecular Genetics of Pituitary Adenomas in Childhood

Cited by 3 publications

References 92 publications

Pediatric pituitary adenomas in Northeast Mexico. A follow-up study

Pediatric pituitary adenomas in Northeast Mexico. A follow-up study

A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas

Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways

Contact Info

Product

Resources

About